BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Equities research analysts at Roth Capital issued their Q1 2017 EPS estimates for BioDelivery Sciences International in a research note issued to investors on Tuesday, Zacks Investment Research reports. Roth Capital analyst S. Henry forecasts that the specialty pharmaceutical company will post earnings per share of $0.09 for the quarter. Roth Capital has a “Buy” rating and a $5.00 price objective on the stock. Roth Capital also issued estimates for BioDelivery Sciences International’s Q2 2017 earnings at ($0.24) EPS, Q3 2017 earnings at ($0.23) EPS, Q4 2017 earnings at ($0.21) EPS, FY2017 earnings at ($0.59) EPS and FY2018 earnings at ($0.55) EPS.
A number of other research analysts have also recently weighed in on BDSI. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, February 8th. Cantor Fitzgerald set a $3.00 price objective on BioDelivery Sciences International and gave the company a “hold” rating in a research note on Tuesday, January 17th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $3.00 price objective on shares of BioDelivery Sciences International in a research note on Monday, March 20th. Finally, FBR & Co reaffirmed a “buy” rating and set a $4.00 price objective on shares of BioDelivery Sciences International in a research note on Monday, March 20th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $3.50.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://baseballnewssource.com/markets/brokers-set-expectations-for-biodelivery-sciences-international-inc-s-q1-2017-earnings-bdsi-updated-updated/525481.html.
BioDelivery Sciences International (NASDAQ:BDSI) remained flat at $1.65 during trading on Thursday. 304,232 shares of the company traded hands. The firm’s 50 day moving average price is $1.87 and its 200-day moving average price is $1.96. The stock’s market capitalization is $90.41 million. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $3.78.
BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Friday, March 17th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.03. The firm had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $6.37 million. BioDelivery Sciences International had a negative net margin of 93.61% and a negative return on equity of 309.49%. BioDelivery Sciences International’s revenue for the quarter was down 87.9% compared to the same quarter last year. During the same period last year, the firm earned $0.19 earnings per share.
In other BioDelivery Sciences International news, CEO Mark A. Sirgo sold 110,895 shares of the firm’s stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $1.90, for a total value of $210,700.50. Following the sale, the chief executive officer now directly owns 1,670,157 shares of the company’s stock, valued at approximately $3,173,298.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders sold 119,250 shares of company stock worth $226,644. 9.00% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. Bank of Montreal Can raised its stake in shares of BioDelivery Sciences International by 2.2% in the third quarter. Bank of Montreal Can now owns 713,805 shares of the specialty pharmaceutical company’s stock worth $1,927,000 after buying an additional 15,515 shares during the last quarter. Searle & CO. increased its position in BioDelivery Sciences International by 27.1% in the fourth quarter. Searle & CO. now owns 234,100 shares of the specialty pharmaceutical company’s stock worth $410,000 after buying an additional 49,850 shares during the period. A.R.T. Advisors LLC increased its position in BioDelivery Sciences International by 174.8% in the fourth quarter. A.R.T. Advisors LLC now owns 98,100 shares of the specialty pharmaceutical company’s stock worth $171,000 after buying an additional 62,400 shares during the period. Oxford Asset Management increased its position in BioDelivery Sciences International by 280.8% in the fourth quarter. Oxford Asset Management now owns 107,945 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 79,599 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in BioDelivery Sciences International during the third quarter worth approximately $217,000. 53.57% of the stock is currently owned by hedge funds and other institutional investors.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with our FREE daily email newsletter.